This 2005 narrative review by Dimitriou et al. synthesizes the molecular and cellular biology of fracture healing. It maps the temporal expression of three signaling tiers — pro-inflammatory cytokines, BMP/TGF-β superfamily members, and angiogenic factors — from hematoma formation through bone remodeling. The review also covers MSC biology, systemic hormonal modulation, and clinical translation of recombinant BMPs.
The molecular framework in this review is directly why we reach for rhBMP-2 in open tibial fractures and rhBMP-7 in established non-unions: both replicate osteoinductive signals that the local biological environment fails to sustain adequately.
When a patient on anti-TNF biologics presents with a fracture, recognize that TNF-α is not merely inflammatory noise — it is required for hypertrophic chondrocyte apoptosis and vascular invasion during endochondral healing. Suppressing it pharmacologically may impair this phase.
When planning surgery near the periosteum. Aggressive debridement, circumferential stripping, or periosteal sacrifice for tumor margins. Remember that the periosteum is the dominant MSC reservoir. Preserving it when oncologically safe is a biologically meaningful decision, not just anatomic tidiness.
The BESTT trial data cited here (n=450) and the Friedlaender rhBMP-7 trial (n=122) remain the foundational RCTs justifying commercial rhBMP use. Know these trials, their populations (open tibial fractures and tibial non-unions, respectively), and their conclusions for board questions on biologic adjuncts.
This 2005 narrative review by Dimitriou et al. synthesizes the molecular and cellular biology of fracture healing. It maps the temporal expression of three signaling tiers — pro-inflammatory cytokines, BMP/TGF-β superfamily members, and angiogenic factors — from hematoma formation through bone remodeling. The review also covers MSC biology, systemic hormonal modulation, and clinical translation of recombinant BMPs.
The molecular framework in this review is directly why we reach for rhBMP-2 in open tibial fractures and rhBMP-7 in established non-unions: both replicate osteoinductive signals that the local biological environment fails to sustain adequately.
When a patient on anti-TNF biologics presents with a fracture, recognize that TNF-α is not merely inflammatory noise — it is required for hypertrophic chondrocyte apoptosis and vascular invasion during endochondral healing. Suppressing it pharmacologically may impair this phase.
When planning surgery near the periosteum. Aggressive debridement, circumferential stripping, or periosteal sacrifice for tumor margins. Remember that the periosteum is the dominant MSC reservoir. Preserving it when oncologically safe is a biologically meaningful decision, not just anatomic tidiness.
The BESTT trial data cited here (n=450) and the Friedlaender rhBMP-7 trial (n=122) remain the foundational RCTs justifying commercial rhBMP use. Know these trials, their populations (open tibial fractures and tibial non-unions, respectively), and their conclusions for board questions on biologic adjuncts.